UnknownPhase 1NCT03921879
Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma
Studying Nodal T-follicular helper cell lymphoma, follicular type
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Oncotartis, Inc.
- Principal Investigator
- Eric Rowinsky, MDOncotartis, Inc.
- Intervention
- OT-82 Dose Escalation(drug)
- Enrollment
- 50 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2021
Study locations (8)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- City of Hope National Medical Center, Duarte, California, United States
- Sylvester Comprehensive Cancer Center, Miami, Florida, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Roswell Park Cancer Institute, Buffalo, New York, United States
- University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States
- Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
- Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03921879 on ClinicalTrials.govOther trials for Nodal T-follicular helper cell lymphoma, follicular type
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06347653Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL)Peking University
- RECRUITINGPHASE1, PHASE2NCT05230680Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS)Won Seog Kim
See all trials for Nodal T-follicular helper cell lymphoma, follicular type →